1. de Alencar JB, Macedo LC, de Barros MF, Rodrigues C, Cadide RC, Sell AM, Visentaine JE. Importance of immune response genes in hemophilia A. Rev Bras Hematol Hemoter 2013; 35(4): 280-6.

2. Oldenburg J, Ivaskeviciusa V, Rosta S, Fregin A, White K, Holinski-Feder E, et al. Evaluation of DHPLC in the analysis of hemophilia A. J Biochem Biophys Methods 2001; 47(1-2): 39-51.

3. Miclea RD, Varma PR, Peng A, Balu-Iyer SV. Development and characterization of lipidic cochleate containing recombinant factor VIII. Biochim Biophys Acta 2007; 1768(11): 2890-8.

4. Fidanci ID, Zulfikar B, Kavakli K, Ar MC, Kilinc Y, Baslar Z, et al. A polymorphism in the IL-5 gene is associated with inhibitor development in severe Hemophilia A patients. Turk J Haematol 2014; 31(1): 17-24.

5. Lu Y, Ding Q, Dai J, Wang H, Wang X. Impact of polymorphisms in genes involved in autoimmune disease on inhibitor development in Chinese patients with haemophilia A. Thromb Haemost 2012; 107(1): 30-6

6. Astermark J, Oldenburg J, Carlson J, Pavlova A, Kavakli K, Berntorp E, et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108(12): 3739-45.

7. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007; 5(2): 263-5.

8. Astermark J, Donfield SM, Gomperts ED, Schwarz J, Menius ED, Pavlova A, et al. The polygenic nature of inhibitors in hemophilia A: Results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Blood 2013; 121(8): 1446-54.

9. Dariavach P, Mattéi MG, Golstein P, Lefranc MP. Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. Eur J Immunol 1988; 18(12): 1901-5.

10. Maurer M, Loserth S, Kolb-Mäurer A, Ponath A, Wiese S, Kruse N, et al. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1+49) alters T-cell activation. Immunogenetics 2002; 54(1): 1-8

11. McCoy KD, Gros GLE. The role of CTLA-4 in the regulation of T cell immune responses. Immunol Cell Biol 1999; 77: 1–10

12. Riley JL, June CH. The CD28 family: A T-cell rheostat for therapeutic control of T-cell activation. Blood 2005; 105(1): 13-21.

13. Rudd CE, Schneider H. Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat Rev Mmunol 2003; 3(7): 544-56.

14. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997; 18(4): 175-82.

15. Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, et al. A new member of the immunoglobulin superfamily CTLA-4. Nature 1987; 328(6127): 267-70.

16. Linsley PS, Nadler SG, Bajorath J, Peach R, Leung HT, Rogers J, et al. Binding stoichiometry of the cytotoxic T lymphocyte-associated molecule-4 (CTLA-4). A disulfide-linked homodimer binds two CD86molecules. J Biol Chem 1995; 270(25): 15417-24.

17. Contardi E, Palmisano GL, Tazzari PL, Martelli AM, Falà F, Fabbi M, et al. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer 2005; 117(4): 538-50.

18. Pistillo MP, Tazzari PL, Palmisano GL, Pierri I, Bolognesi A, Ferlito F, Capanni P, et al. CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood 2003; 101(1): 202-9.

19. Teft WA, Kirchhof MG, Madrenas J. A molecular perspective of CTLA-4 function. Annu Rev Immunol 2006; 24: 65-97.

20. Lee CA, Berntrop EE, Keith Hoots W. Text book of hemophilia. 2nd ed. Massachusetts: Blackwell 2005; 54-80.

21. Hoyer LW. Why do so many haemophilia A patients develop an inhibitor? Br J Haematol 1995; 90(3): 498-501.

22. Vennylen J. How do some hemophiliacs develop inhibitors? Hemophilia 1988; 4(4): 538-42.

23. Kreuz W, Becker S, Lenz E, Martinez-Saguer I, Escuriola-Ettingshausen C, Funk M, et al. Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII. Semin Thromb Hemost 1995; 21(4): 382-9.

24. Brettler D. Inhibitor of factor VIII and IX. Hemophilia 1995; 1(1): 35-9.

25. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9(4): 418-35.

26. Rothschild C, Laurian Y, Satre EP, Borel Derlon A, Chambost H, Moreau P, et al. French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII: incidence of inhibitor and evaluation of immune tolerance. Thromb Haemost 1998; 80(5): 779-83.

27. Mehdizadeh M, Kardoost M, Zamani G, Baghaeepour MR, Sadeghian K, Pourhoseingholi MA. Occurrence of haemophilia in Iran. Haemophilia 2009; 15(1): 348-51.

28. Schoppmann A, Waytes AT. Factor VIII inhibitor and severity of hemophilia. Thromb Haemost 1996; 76(2): 280-1.

29. Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J, et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34(2): 869-72.

30. Sharifian R, Hoseini M, Safai R, Tugeh Gh, Ehsani AH, Lak M, et al. Prevalence of inhibitors in a population of 1280 hemophilia a patients in Iran. Acta Medica Iranica 2003; 41(1): 66-8.

31. Zahedi MJ, Darvish Moghadam S. [Frequency of hepatitis B and C infection among hemophilic patients in kerman (Persian)]. J Kerman Univ Med Sci 2004; 11(3): 131-5.

32. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Günger T, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339(8793): 594-8.

33. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL-10 but not in the IL-1b and IL-4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167-72

34. Ligers A, Teleshova N, Masterman T, HuangWX, Hillert J. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun 2001; 2(3): 145-52.

35. Wang XB, Zhao X, Giscombe R, Lefvert AK. A CTLA-4 gene polymorphism at position -318 in the promoter region affects the expression of protein. Genes Immun 2002; 3(4): 233-4.

36. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007; 5 (2): 263-5

37. Pavlova A, Delev D, Lacroix-Desmazes S, Schwaab R, Mende M, Fimmers R, et al. Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-a and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. J Thromb Haemost 2009; 7 (12): 2006-15.

38. Zhang LL, Yu ZQ, Zhang W, Cao LJ, Su J, Bai X, Ruan CG. Relationship between factor VIII inhibitor development and polymorphisms of TNFα and CTLA-4 gene in Chinese Han patients with hemophilia A. Zhonghua Xue Ye Xue Za Zhi 2011; 32(3): 168-72.

39. Lu Y, Ding Q, Dai J, Wang H, Wang X. Impact of polymorphisms in genes involved in autoimmune disease on inhibitor development in Chinese patients with haemophilia A. Thromb Haemost 2012; 107(1): 30-6.

40. Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 2006; 12(6):15-22.

41. Walsh CE, Soucie JM, Miller CH. Impact of inhibitors on hemophilia A mortality in the United States. Am J Hematol 2015; 90(5): 400-5.